Brokerages Set Tyra Biosciences, Inc. (NASDAQ:TYRA) PT at $32.00

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have received an average rating of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $32.00.

A number of equities research analysts recently issued reports on the stock. Oppenheimer reiterated an “outperform” rating and set a $36.00 target price on shares of Tyra Biosciences in a research report on Wednesday, September 10th. Raymond James Financial assumed coverage on shares of Tyra Biosciences in a research report on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Friday, August 22nd. Wall Street Zen upgraded shares of Tyra Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, October 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, October 8th.

Tyra Biosciences Stock Performance

NASDAQ:TYRA opened at $14.82 on Monday. The company has a 50-day moving average of $13.52 and a 200-day moving average of $11.39. The company has a market capitalization of $789.91 million, a price-to-earnings ratio of -8.33 and a beta of 1.12. Tyra Biosciences has a 52 week low of $6.42 and a 52 week high of $17.78.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.50) EPS for the quarter, hitting analysts’ consensus estimates of ($0.50). Sell-side analysts forecast that Tyra Biosciences will post -1.57 EPS for the current year.

Institutional Investors Weigh In On Tyra Biosciences

A number of hedge funds have recently made changes to their positions in TYRA. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Tyra Biosciences in the 1st quarter valued at about $84,000. US Bancorp DE increased its position in Tyra Biosciences by 50.5% in the 1st quarter. US Bancorp DE now owns 5,435 shares of the company’s stock valued at $51,000 after acquiring an additional 1,823 shares in the last quarter. Swiss National Bank increased its position in Tyra Biosciences by 42.0% in the 1st quarter. Swiss National Bank now owns 29,400 shares of the company’s stock valued at $273,000 after acquiring an additional 8,700 shares in the last quarter. Nuveen LLC acquired a new stake in Tyra Biosciences in the 1st quarter valued at about $465,000. Finally, American Century Companies Inc. increased its position in Tyra Biosciences by 5.8% in the 1st quarter. American Century Companies Inc. now owns 23,431 shares of the company’s stock valued at $218,000 after acquiring an additional 1,289 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.